Gene Editing Technology Holds Promise to Eradicate HIV in the Future
- Paternal Microbiome Perturbations Impact Offspring Fitness
- New Report Casts Doubt on Maradona’s Cause of Death and Rocks Manslaughter Case
- Chinese academician unable to provide the exact source of liver transplants
- Early Biomarker for Multiple Sclerosis Development Identified Years in Advance
- Aspirin Found Ineffective in Improving Recurrence Risk or Survival Rate of Breast Cancer Patients
- Child Products from Aliexpess and Temu Contain Carcinogens 3026x Over Limit
CRISPR-Cas9 Gene Editing Technology EBT-001 Holds Promise to Eradicate HIV in the Future
- AstraZeneca Admits for the First Time that its COVID Vaccine Has Blood Clot Side Effects
- Was COVID virus leaked from the Chinese WIV lab?
- HIV Cure Research: New Study Links Viral DNA Levels to Spontaneous Control
- FDA has mandated a top-level black box warning for all marketed CAR-T therapies
- Can people with high blood pressure eat peanuts?
- What is the difference between dopamine and dobutamine?
- How long can the patient live after heart stent surgery?
CRISPR-Cas9 Gene Editing Technology EBT-001 Holds Promise to Eradicate HIV in the Future
August 18 – Scientists from Temple University’s Lewis Katz School of Medicine in the United States have recently reported that the CRISPR-Cas9 gene editing technology known as EBT-001 has the potential to safely and effectively remove SIV (Simian Immunodeficiency Virus) from the genomes of non-human primates.
This pre-clinical research represents a significant step forward in the pursuit of HIV therapy for humans, with the related paper published online in the “Gene Therapy” journal.
The research team, including Dr. Kamel Khalili, Dr. Tricia Burdo, and HIV researchers from Temple University, conducted experiments with EBT-001 in rhesus macaques, a tool specifically designed to target the SIV pre-viral DNA.
The findings demonstrate that EBT-001 efficiently eliminated SIV, which had been dormant in the viral reservoirs within the host’s DNA, with no off-target effects observed in the animals.
This novel technology aims to permanently inactivate the virus within large animal model tissues using a one-time injection treatment method, and the safety of this approach has been confirmed through these pre-clinical trials in non-human primates.
The team packaged the SIV-specific CRISPR-Cas9 gene editing construct, EBT-001, into an adeno-associated virus 9 (AAV9) vector, which can be delivered into the bodies of SIV-infected animals through intravenous injection.
This achievement lays the foundation for the ongoing EBT-101 clinical trials, marking not only a significant milestone in HIV virus research but also advancing the development of multiple gene editing therapies for other infectious diseases like herpes simplex virus and hepatitis B.
(source:internet, reference only)
Disclaimer of medicaltrend.org
Important Note: The information provided is for informational purposes only and should not be considered as medical advice.
